Status:
COMPLETED
AVS After 1mg DST to Determine Subtype in PA
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Primary Aldosteronism
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To compare the effect of different procedures of AVS(after 1mg DST or not) in determining the subtypes and long-term outcomes of PA
Detailed Description
All paticipants will be randomly divided into 1mg DST group(Intervention group,n=43) and placebo group(Control group,n=43) and to determining the subtypes and to compare the long-term outcomes of pati...
Eligibility Criteria
Inclusion
- Age 18 or above, male or female, with legal capacity;
- Patients who diagnosed as primary aldosteronism and willing to surgery
Exclusion
- Pregnant or lactating women
- Patients with a history of malignant tumors or complicated with severe heart disease, eGFR\<30ml/min/1.73m2, severe anemia (Hb\<60g/L), stroke or acute coronary syndrome within 3 months, severe liver disease
- Having contraindications or refusal to undergo AVS or unilateral adrenalectomy, or allergy to ACTH;
- PA combined with Cushing syndrome (including subclinical Cushing); or considering glucocorticoid-suppressible aldosteronism (GRA) or adrenocortical carcinoma;
Key Trial Info
Start Date :
January 8 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2022
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT04709185
Start Date
January 8 2021
End Date
December 30 2022
Last Update
June 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Hospital, Fudan University
Shanghai, China